A substantial advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This updated offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and https://wearethelist.com/story23468092/groundbreaking-development-tirzepatide-dose-for-diabetes-management